New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
...r Bavituximab II-60 Jenken to Commence Phase II Trial of JBK-122 II-60 Pevion Biotech Initiates Phase I Study of Hepatitis C Vaccine II-61 intercell Releases Phase II Findings of IC41 II-61 6. Recent Industry Activity II-62 Three Rivers Acquires Infergen(R) II-62 International Consolid...Intercell to Webcast Research & Development Day on Thursday, June 4, 2009
...ENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that it will webcas...tious disease and the primary investigator for the intercell Travelers' Diarrhea Phase II clinical trial. Dr. D...rs. In addition to Dr. DuPont, members of the intercell management team will make presentations including,...Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military
... - Exclusive, multi-year contract executed by intercell and U.S. Department of Defense for purchase of IXI... soon VIENNA, May 8 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL; OTC Bulletin Board: INRLY) announce...as follows: Exclusive contract for intercell to supply DLA with all their requirements for JE v...Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
... is a result of an excellent collaboration between intercell and the Walter Reed Army Institute of Research in ...ry VIENNA, March 31 /PRNewswire-FirstCall/ -- intercell AG (VSE: ICLL) today announced FDA approval of its...ant contribution towards development of IXIARO and intercell is very appreciative of this outstanding collabora...Huntsworth plc Releases Interim Statement on First Quarter 2008
...n. New European clients for Huntsworth Health include Daiichi-Sankyo, Pfizer and Novartis Vaccines, and global accounts won include Roche, Novartis, intercell and Iroko. Our multi-disciplinary business is also increasing, and whilst most clients still offer new projects and pitches in one area (advertising o...Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT
...l/ -- Iomai Corporation (Nasdaq: IOMI ) today said that it will host a conference call and live webcast tomorrow to discuss today's announcement that intercell AG (VSE: ICLL) and Iomai have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a...Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008
...l Development, Genentech * David P. Meeker, MD, President, LSD Therapeutics, Genzyme * Eszter Nagy, MD, PhD, Vice President, Pre-clinical R&D, intercell * Steve J. Offord, PhD, Vice President CNS New Products Marketing, Market Access and Business Development, sanofi-aventis * Carlos Plata-Salam...Intercell to Begin Phase II JE Vaccine Trials in India
... Austrian biotech major, intercell and its partner Hyderabad-based Biological E. Ltd. announced that they have obtained regulatory clearance to start// a pediatric phase II clinical tri...Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
...orted by PATH VIENNA, April 7 /PRNewswire/ -- intercell AG (VSE: ICLL) announced today that a Phase I clin...ase I trial. Under the terms of the collaboration, intercell will develop the vaccine and make it available at ...is and Otitis media in young children. About intercell AG ...Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
... VIENNA, Austria, Sept. 3 /PRNewswire/ -- Today, intercell AG (ICLL) announced the six months follow up data ...sting and future HCV combination treatments. Thus, intercell will follow its development strategy that will als...seen to expand to about EUR 3.5bn by 2006. About intercell AG ...Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
... VIENNA, Austria, May 18, 2007 – intercell AG (VSE, “ICLL”) has been informed by ... increasingly difficult and challenging. About intercell AG: Intercell AG is a growing biotechnology company which focuses on the design and intercell AG is a growing biotechnology company which focus...Iomai Stockholders Approve Merger With Intercell Subsidiary
GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) announced today that its stockholders approved the merger of Iomai with a wholly-owned subsidiary of Intercell AG. Approximately 71.6 percent of Iomai's outstanding shares entitled to vote at the special mee...Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
...December 2008 VIENNA, April 2 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that its new vaccin... study with JE-VAX(R). About intercell AG intercell AG is an innovative biotechnology company that des...Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
... for Q2 2009 VIENNA, March 30 /PRNewswire/ -- intercell AG (VSE: ICLL) today announced that the U.S. Food ...d certain other markets in Asia and Latin America. intercell will directly distribute and market IXIARO to the ... study with JE-VAX(R). About intercell AG ...Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
... FAES FARMA SA (SIBE Spain: FAE) GPC BIOTECH AG (NASDAQ: GPC ) GRIFOLS SA (SIBE Spain: GRF) H LUNDBECK A/S (OMX Nordic Exchange Copenhagen: LUN) intercell AG (Wiener Bourse, Austria: ICLL) RICHTER GEDEON NYRT (Budapest, Hungary: RICHTBO) STADA ARZNEIMITTEL AG (Frankfurt, Germany: SAZ) ZELTIA SA (SIBE ...Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
...technology with regard to the use of certain fusion proteins in the development of a tuberculosis vaccine. The license from SSI includes access to the intercell IC31(R) adjuvant. If the development is successful, sanofi pasteur would manufacture the vaccine commercially. SSI TB vaccine candidates are recombi...